Will Johnson & Johnson say “Nipocalimab / Lupus”?
Johnson & Johnson did not say “Nipocalimab / Lupus” on its Oct 13, 2026 call (FY26 Q3); it said it on 2 of its last 8 calls: 2, 0, 0, 0, 1, 0, 0, 0 times. As of Oct 24, 2026, Johnson & Johnson said “Nipocalimab / Lupus” on 1 of 4 calls with a settled Kalshi or Polymarket mention market since Jan 21, 2026 (25%), most recently on Jan 21, 2026. Parrot’s p for the next listing is 22% (n=4, from settlement history blended with transcripts), not a forecast.
- Last 10
- 1/4Last 10 settled, oldest to newest: yes no no no
- Streak
- not said the last 3 times
- Counts
- company speakers + operator
- Market
- 21¢ Kalshi (may be delayed)
Where it was said
quotes of at most 25 words; select an appearance
Johnson & Johnson
Nipocalimab / Lupus
- Probability
- 22% · n=4
- Settled
- 1/4 (25%)
- Last calls
- said in 2 of 8
Next listing counts: company speakers + operator
Counts: company speakers + operator
1 counted (0 in prepared remarks, 1 in Q&A).
…spoken about yet today, but areas such as Sjogren's disease and SLE, lupus, areas of really high unmet medical need. Atopic dermatitis, of which we…
Counts: company speakers + operator (not listed here; the usual rule)
2 counted (2 in prepared remarks, 0 in Q&A).
…monotherapy for adults with treatment resistant depression. We received priority review for Nipocalimab for the treatment of generalized myasthenia gravis in addition to the FDA…
…Innovative Medicine, this includes expected approvals for TREMFYA subcutaneous for Crohn's disease, nipocalimab for generalized myasthenia gravis and subcutaneous RYBREVANT for non-small cell lung…
Every settled listing
newest first · 5 shown| Date | Listed as | Venue | Result | Our count |
|---|---|---|---|---|
| Oct 13, 2026 | Nipocalimab / Lupus |  Kalshi | No | 0 |
| Jul 15, 2026 | Nipocalimab / Lupus | Kalshi | No | 0 |
| Apr 14, 2026 | Nipocalimab / Lupus | Kalshi | No | 0 |
| Jan 21, 2026 | Nipocalimab / Lupus |  Polymarket | Yes | 1 |
| Jan 21, 2026 | Nipocalimab / Lupus | Kalshi | Yes | 1 |
Questions
- How many times did Johnson & Johnson say “Nipocalimab / Lupus” on its last earnings call?
- Johnson & Johnson did not say “Nipocalimab / Lupus” on its Oct 13, 2026 call (FY26 Q3); it said it on 2 of its last 8 calls: 2, 0, 0, 0, 1, 0, 0, 0 times.
- How often does Johnson & Johnson say “Nipocalimab / Lupus”?
- As of Oct 24, 2026, Johnson & Johnson said “Nipocalimab / Lupus” on 1 of 4 calls with a settled Kalshi or Polymarket mention market since Jan 21, 2026 (25%), most recently on Jan 21, 2026.
- What is the probability Johnson & Johnson says “Nipocalimab / Lupus” next time?
- 22%, from settlement history blended with transcripts (n=4). It is a base rate from history, not a forecast and not advice.
- Who has to say it for the market to count?
- Under the next market's rule: company speakers + operator.
Cite parrot.markets, “Johnson & Johnson: ‘Nipocalimab / Lupus’ mention history”, as of Oct 24, 2026, https://parrot.markets/earnings/JNJ/words/lupus-or-nipocalimab (CC BY 4.0)
Agents: this page as TSV at /api/v1/word?entity=johnson-and-johnson&word=lupus%20%2F%20nipocalimab · quotes: /api/v1/quotes?entity=johnson-and-johnson&word=… · columnar JSON in #parrot-data · llms.txt · MCP